Comparing SLU-PP-332 and SLU-PP-915: Molecular Mechanics, Receptor Selectivity, and Preclinical Delivery of Pan-ERR Agonists
1. The Evolution of Estrogen-Related Receptor (ERR) Pan-Agonism
In the study of cellular bioenergetics and metabolic signaling, the Estrogen-Related Receptor (ERR) family of orphan nuclear receptors—comprising ERRα (NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3)—functions as a master transcriptional regulator. Cooperating closely with the transcriptional coactivator Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha (PGC-1α), ERRs control genomic programs governing mitochondrial biogenesis, oxidative phosphorylation (OXPHOS), fatty acid β-oxidation (FAO), and contractile protein remodeling in high-energy demand tissues.
Historically, chemical interrogation of the ERR pathway was restricted by a lack of potent, synthetic small-molecule agonists capable of overcoming native ligand-independent receptor conformations. The discovery of SLU-PP-332 established a proof-of-concept, demonstrating that small-molecule activation of ERR isoforms can induce acute exercise-mimetic transcriptional responses in cell cultures and rodent models.
However, structural and pharmacokinetic hurdles with early-generation ligands prompted the synthesis of SLU-PP-915. This second-generation compound was engineered to resolve critical solubility and systemic delivery challenges while altering the relative subtype binding stoichiometry across ERRα, ERRβ, and ERRγ. Understanding the pharmacological distinctions between these two benchmark research probes is essential for designing rigorous in vitro and animal-model metabolic assays.
2. Chemical and Molecular Specifications
While both compounds are classified as synthetic pan-ERR agonists, they occupy distinct chemical classes and exhibit divergent molecular weights, functional groups, and subtype binding parameters:
| Parameter | SLU-PP-332 (First-Generation) | SLU-PP-915 (Second-Generation) |
|---|---|---|
| Chemical Scaffold | Substituted Benzohydrazide Derivative | 2,5-Disubstituted Thiophene Derivative |
| CAS Number | 303760-60-3 (Alt: 2922116-85-2) | 2285432-92-8 |
| Chemical Formula | C18H14N2O2 | C17H13BFNO3S |
| Molecular Weight | 290.32 g/mol | 341.16 g/mol |
| IUPAC Designation | 4-hydroxy-N’-[(1E)-naphthalen-2-ylmethylidene]benzohydrazide | [5-[4-(4-fluorophenyl)-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl]thiophen-2-yl]boronic acid derivative |
| ERRα Potency (EC50) | ≈ 98 nM (High Potency) | ≈ 414 nM (Moderate Potency) |
| ERRβ Potency (EC50) | ≈ 230 nM | ≈ 435 nM |
| ERRγ Potency (EC50) | ≈ 428 nM | ≈ 378 nM |
| Subtype Selectivity Profile | ERRα-Preferring (~4.4-fold over ERRγ) | Balanced / Flat Pan-Agonist (Equipotent across α, β, γ) |
| Preclinical Route Suitability | Parenteral / Intraperitoneal (Poor Oral Uptake) | Orally Bioavailable in Murine Models |
| Primary Academic Literature | PMID: 36988910 | PMID: 37739806 | PMID: 41421047 | PMC10842599 |
3. Receptor Binding Kinetics: ERRα-Preference vs. Balanced Pan-Agonism
The fundamental pharmacological divergence between SLU-PP-332 and SLU-PP-915 lies in their subtype activation profiles:
- SLU-PP-332 (ERRα-Preferring): Demonstrating an EC50 of 98 nM at ERRα compared to 428 nM at ERRγ, SLU-PP-332 displays an approximate 4.4-fold preference for ERRα. Because ERRα is the dominant isoform driving fatty acid oxidation and mitochondrial respiration in skeletal myoblasts, SLU-PP-332 serves as a highly potent probe for isolated cellular assays investigating direct muscle fiber metabolic reprogramming.
- SLU-PP-915 (Flat Pan-Agonist): Structural optimization of the thiophene backbone yielded a compound with balanced, sub-micromolar affinity across all three receptor isoforms (ERRα: 414 nM; ERRβ: 435 nM; ERRγ: 378 nM). While absolute potency at ERRα is approximately four-fold lower than that of SLU-PP-332, SLU-PP-915 demonstrates superior relative engagement of ERRγ. This balanced profile is advantageous in cardiac and renal tissue explants where ERRγ plays a primary regulatory role in maintaining physiological metabolic homeostasis.
4. Preclinical Pharmacokinetics: Solving the Oral Bioavailability Challenge
For laboratory researchers moving from in vitro multi-well plates to in vivo rodent metabolic models, drug delivery kinetics represent the primary operational factor:
- SLU-PP-332 Limitations in Whole-Animal Protocols: Despite its high in vitro potency, SLU-PP-332 displays unfavorable physicochemical properties and rapid first-pass clearance, resulting in poor oral bioavailability. Consequently, published preclinical rodent studies rely almost exclusively on intraperitoneal (IP) injections (typically formulated in specialized DMSO/PEG vehicles) to achieve target plasma thresholds.
- SLU-PP-915 Oral Optimization: Engineered specifically to overcome this delivery hurdle, SLU-PP-915 exhibits robust oral bioavailability in mice. Preclinical data published in the Journal of Pharmacology and Experimental Therapeutics (PMID: 41421047) demonstrate that oral administration of SLU-PP-915 successfully engages nuclear ERR targets, elevating whole-body aerobic capacity and running endurance in animal treadmill assays without requiring invasive parenteral administration.
5. Downstream Transcriptional Cascades and Cellular Outcomes
Both molecules stimulate downstream genomic cascades that mimic cellular responses to aerobic exercise, yet they exhibit distinct transcriptional signatures:
- Ddit4 Gene Transactivation: Both compounds induce the transcription of Ddit4 (DNA damage-inducible transcript 4), an endogenous cellular marker reliably upregulated by acute endurance exercise. In comparative murine studies, oral SLU-PP-915 induced Ddit4 expression to levels matching or exceeding high-intensity treadmill protocols.
- Type IIa Oxidative Fiber Switching: Incubation of skeletal myoblasts with SLU-PP-332 upregulates myosin heavy chain IIa expression and increases basal and maximal oxygen consumption rates (OCR) during extracellular flux analysis, modeling the transformation of glycolytic muscle fibers into fatigue-resistant oxidative fibers.
- Cardioprotective and Anti-Fibrotic Remodeling: In murine transverse aortic constriction (TAC) models of pressure-overload heart failure, both pan-ERR agonists normalized cardiac lipid metabolomics, improved left ventricular ejection fraction, and attenuated fibrotic tissue remodeling (PMC10842599). The elevated ERRγ engagement of SLU-PP-915 provides specific advantages in cardiac tissue models where ERRγ expression is highest.
Frequently Asked Questions (FAQs)
1. What is the main difference between SLU-PP-332 and SLU-PP-915?
The primary differences lie in receptor subtype selectivity and oral bioavailability. SLU-PP-332 is an ERRα-preferring agonist (EC50 ≈ 98 nM) with poor oral bioavailability, requiring intraperitoneal administration in animal protocols. SLU-PP-915 is a chemically distinct thiophene derivative with a balanced, flat pan-ERR profile across α, β, and γ subtypes (EC50 ≈ 378–435 nM) engineered specifically for oral bioavailability in preclinical models.
2. Is SLU-PP-332 more potent than SLU-PP-915?
At the ERRα receptor subtype, SLU-PP-332 is roughly four-fold more potent than SLU-PP-915 (98 nM vs. 414 nM). However, at the ERRγ receptor subtype, SLU-PP-915 demonstrates slightly higher relative potency (378 nM vs. 428 nM). In whole-animal oral studies, SLU-PP-915 displays superior functional activity due to its vastly improved pharmacokinetic profile.
3. Are SLU-PP-332 and SLU-PP-915 peptides?
No. Neither SLU-PP-332 nor SLU-PP-915 are peptides. They are synthetic, non-peptidic small molecules that act as ligand agonists on nuclear receptor proteins. They do not consist of amino acid chains and are not subject to standard peptidase degradation pathways.
4. What are the recommended laboratory solubility parameters for these compounds?
Both compounds exhibit high lipophilicity and negligible solubility in plain water. For analytical and in vitro assay preparation, stock solutions should be prepared in dimethyl sulfoxide (DMSO) at concentrations of 10–50 mM before subsequent dilution into aqueous culture media, maintaining DMSO final concentrations below 0.1% v/v to avoid cellular toxicity.
5. Which compound is more appropriate for specific laboratory models?
For isolated cell culture assays (e.g., C2C12 myoblasts or HepG2 hepatocytes) focused specifically on high-potency ERRα activation, SLU-PP-332 provides maximal target potency. For whole-animal studies requiring non-invasive oral administration or models focused on cardiac ERRγ signaling, SLU-PP-915 is the preferred reference standard.
6. Where can analytical-grade SLU-PP-332 and SLU-PP-915 be sourced for research?
Analytical reference standards of both compounds can be obtained directly through Modern Aminos via their dedicated product pages: SLU-PP-332 and SLU-PP-915. Every batch is verified via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to confirm minimum 98%+ active chemical purity.